Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases (vol 18, 1198, 2018)

被引：3
|
作者：
Tan, Wan-Ling [1 ]
Ng, Quan Sing [1 ]
Lim, Cindy [2 ]
Tan, Eng Huat [1 ]
Toh, Chee Keong [1 ]
Ang, Mei-Kim [1 ]
Kanesvaran, Ravindran [1 ]
Jain, Amit [1 ]
Tan, Daniel S. W. [1 ,3 ]
Lim, Darren Wan-Teck [1 ,4 ]
机构：
[1] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Clin Trials & Epidemiol Sci, Singapore, Singapore
[3] ASTAR, Genome Inst Singapore, Singapore, Singapore
[4] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore
来源：
BMC CANCER | 2018年 / 18卷
关键词：
D O I：
10.1186/s12885-018-5215-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ᅟ
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
    Wan-Ling Tan
    Quan Sing Ng
    Cindy Lim
    Eng Huat Tan
    Chee Keong Toh
    Mei-Kim Ang
    Ravindran Kanesvaran
    Amit Jain
    Daniel S. W. Tan
    Darren Wan-Teck Lim
    [J]. BMC Cancer, 18
  • [2] Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
    Tan, Wan-Ling
    Ng, Quan Sing
    Lim, Cindy
    Tan, Eng Huat
    Toh, Chee Keong
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Jain, Amit
    Tan, Daniel S. W.
    Lim, Darren Wan-Teck
    [J]. BMC CANCER, 2018, 18
  • [3] Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
    Wan-Ling Tan
    Quan Sing Ng
    Cindy Lim
    Eng Huat Tan
    Chee Keong Toh
    Mei-Kim Ang
    Ravindran Kanesvaran
    Amit Jain
    Daniel S. W. Tan
    Darren Wan-Teck Lim
    [J]. BMC Cancer, 18
  • [4] Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases
    Nadler, E.
    Pavilack, M.
    Espirito, J.
    Baidoo, B.
    Fernandes, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S383 - S383
  • [5] Outcomes of EGFR-mutant NSCLC patients with de novo brain metastases by upfront treatment
    Ma, J.
    Li, Y.
    Lai, G. G. Y.
    Tan, E-H.
    Lim, W. D. T.
    Ang, M-K.
    Ng, Q. S.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Fong, K. W.
    Siow, T. R.
    Thiagarajan, A.
    Yap, S. P.
    Chia, S. H. B.
    Ng, W. L.
    Tan, D. S. W.
    Tan, S. H.
    Tan, W. L.
    Chua, K. L. M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S970 - S970
  • [6] Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
    Igawa, S.
    Ono, T.
    Kasajima, M.
    Yamada, K.
    Oguri, A.
    Kameda, A.
    Yamamoto, H.
    Kakegawa, M.
    Hiyoshi, Y.
    Kusuhara, S.
    Ozawa, T.
    Otani, S.
    Fukui, T.
    Mitsufuji, H.
    Masaru, K.
    Yokoba, M.
    Kubota, M.
    Sasaki, J.
    Naoki, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S611 - S611
  • [7] Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
    How, Soon Hin
    Liam, Chong Kin
    Abidin, Muhammad Adil Zainal
    Hasbullah, Harissa H.
    Tho, Lye Mun
    Ho, Gwo Fuang
    Nor, Ibtisam Muhamad
    Pang, Yong Kek
    Ho, Kean Fatt
    Thiagarajan, Muthukkumaran
    Ariffin, Roziana
    Samsudin, Azlina
    Omar, Azza
    Tan, Sin Nee
    Ong, Choo Khoon
    Soon, Sing Yang
    Poh, Mau Ern
    [J]. CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1995 - 2005
  • [8] High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
    Fan, Y.
    Zhu, J.
    He, J.
    Zhou, R.
    Chen, J.
    Han, G.
    Ren, B. Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1585 - S1585
  • [9] Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases
    Miyawaki, Eriko
    Kenmotsu, Hirotsugu
    Harada, Hideyuki
    Mitsuya, Koichi
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakasu, Yoko
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
12345